Dr. Pamela Kunz covering the Gastroenterology ASCO 2024
In discussion with Dr. Pamela Kunz covering the Gastroenterology ASCO 2024 meeting highlights from Community Oncology perspective.
August 24, 2024
Conferences
GI ASCO
2024
Key Points
CheckMate 8HW: Nivolumab plus ipilimumab vs chemotherapy as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer
EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization combined with durvalumab with or without bevacizumab in participants with unresectable hepatocellular carcinoma eligible for embolization
NETTER-2: [177Lu]Lu-DOTA-TATE in newly diagnosed patients with advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors
